影响拉帕替尼和卡培他滨联合治疗her2阳性转移性乳腺癌患者无进展生存期的预后因素

İzzet Doğan, Nail Paksoy, Naziye Ak, Sezai Vatansever, Pınar Saip, Adnan Aydıner
{"title":"影响拉帕替尼和卡培他滨联合治疗her2阳性转移性乳腺癌患者无进展生存期的预后因素","authors":"İzzet Doğan,&nbsp;Nail Paksoy,&nbsp;Naziye Ak,&nbsp;Sezai Vatansever,&nbsp;Pınar Saip,&nbsp;Adnan Aydıner","doi":"10.4274/ejbh.galenos.2023.2022-12-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim was to assess the prognostic variables in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients receiving lapatinib plus capecitabine.</p><p><strong>Materials and methods: </strong>Retrospective data on HER2-positive metastatic breast cancer patients who received lapatinib and capecitabine were analyzed. Survival outcome was obtained with Cox regression analysis and the Kaplan-Meier method.</p><p><strong>Results: </strong>The study included 102 patients. Forty-four (43.1%) patients had <i>de novo</i> metastatic disease. The most frequent metastatic sites were, in order, bone (61.8%), brain (57.8%), liver (35.3%), and lung (34.3%). All of the patients had previously received chemotherapy based on trastuzumab. With combined lapatinib and capecitabine, complete response was observed in 7.8%, partial response in 30.4%, and stable disease in 24.5%. Progression-free survival was 8 (95% confidence interval, 5.1-10.8) months. In multivariable analysis, endocrine therapy (<i>p</i> = 0.02), <i>de novo</i> metastatic disease (<i>p</i> = 0.02), and age (<i>p</i> = 0.02) were prognostic factors for progression-free survival. However, the number of chemotherapy cycles with trastuzumab, palliative radiotherapy, history of breast surgery, and the number of metastatic sites were not significant in this respect.</p><p><strong>Conclusion: </strong>These results have demonstrated the effectiveness of lapatinib plus capecitabine in metastatic HER2-positive breast cancer patients. Furthermore, unfavorable prognostic factors for progression-free survival were shown to be hormone-negative tumor, <i>de novo</i> metastatic disease, and young age.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"19 2","pages":"128-133"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071882/pdf/ejbh-19-128.pdf","citationCount":"0","resultStr":"{\"title\":\"Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine.\",\"authors\":\"İzzet Doğan,&nbsp;Nail Paksoy,&nbsp;Naziye Ak,&nbsp;Sezai Vatansever,&nbsp;Pınar Saip,&nbsp;Adnan Aydıner\",\"doi\":\"10.4274/ejbh.galenos.2023.2022-12-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The aim was to assess the prognostic variables in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients receiving lapatinib plus capecitabine.</p><p><strong>Materials and methods: </strong>Retrospective data on HER2-positive metastatic breast cancer patients who received lapatinib and capecitabine were analyzed. Survival outcome was obtained with Cox regression analysis and the Kaplan-Meier method.</p><p><strong>Results: </strong>The study included 102 patients. Forty-four (43.1%) patients had <i>de novo</i> metastatic disease. The most frequent metastatic sites were, in order, bone (61.8%), brain (57.8%), liver (35.3%), and lung (34.3%). All of the patients had previously received chemotherapy based on trastuzumab. With combined lapatinib and capecitabine, complete response was observed in 7.8%, partial response in 30.4%, and stable disease in 24.5%. Progression-free survival was 8 (95% confidence interval, 5.1-10.8) months. In multivariable analysis, endocrine therapy (<i>p</i> = 0.02), <i>de novo</i> metastatic disease (<i>p</i> = 0.02), and age (<i>p</i> = 0.02) were prognostic factors for progression-free survival. However, the number of chemotherapy cycles with trastuzumab, palliative radiotherapy, history of breast surgery, and the number of metastatic sites were not significant in this respect.</p><p><strong>Conclusion: </strong>These results have demonstrated the effectiveness of lapatinib plus capecitabine in metastatic HER2-positive breast cancer patients. Furthermore, unfavorable prognostic factors for progression-free survival were shown to be hormone-negative tumor, <i>de novo</i> metastatic disease, and young age.</p>\",\"PeriodicalId\":11885,\"journal\":{\"name\":\"European journal of breast health\",\"volume\":\"19 2\",\"pages\":\"128-133\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071882/pdf/ejbh-19-128.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of breast health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/ejbh.galenos.2023.2022-12-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of breast health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/ejbh.galenos.2023.2022-12-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:评估人表皮生长因子受体2 (HER2)阳性转移性乳腺癌患者接受拉帕替尼加卡培他滨治疗后的预后变量。材料和方法:回顾性分析her2阳性转移性乳腺癌患者接受拉帕替尼和卡培他滨治疗的资料。生存结局采用Cox回归分析和Kaplan-Meier法。结果:纳入102例患者。44例(43.1%)患者有新发转移性疾病。最常见的转移部位依次为骨(61.8%)、脑(57.8%)、肝(35.3%)和肺(34.3%)。所有患者之前都接受过基于曲妥珠单抗的化疗。联合使用拉帕替尼和卡培他滨,完全缓解率为7.8%,部分缓解率为30.4%,病情稳定率为24.5%。无进展生存期为8个月(95%可信区间,5.1-10.8)。在多变量分析中,内分泌治疗(p = 0.02)、新发转移性疾病(p = 0.02)和年龄(p = 0.02)是无进展生存期的预后因素。然而,曲妥珠单抗化疗周期、姑息性放疗、乳房手术史和转移部位数量在这方面没有显著性差异。结论:这些结果证明了拉帕替尼联合卡培他滨治疗转移性her2阳性乳腺癌患者的有效性。此外,无进展生存期的不利预后因素显示为激素阴性肿瘤、新发转移性疾病和年轻。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine.

Objective: The aim was to assess the prognostic variables in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients receiving lapatinib plus capecitabine.

Materials and methods: Retrospective data on HER2-positive metastatic breast cancer patients who received lapatinib and capecitabine were analyzed. Survival outcome was obtained with Cox regression analysis and the Kaplan-Meier method.

Results: The study included 102 patients. Forty-four (43.1%) patients had de novo metastatic disease. The most frequent metastatic sites were, in order, bone (61.8%), brain (57.8%), liver (35.3%), and lung (34.3%). All of the patients had previously received chemotherapy based on trastuzumab. With combined lapatinib and capecitabine, complete response was observed in 7.8%, partial response in 30.4%, and stable disease in 24.5%. Progression-free survival was 8 (95% confidence interval, 5.1-10.8) months. In multivariable analysis, endocrine therapy (p = 0.02), de novo metastatic disease (p = 0.02), and age (p = 0.02) were prognostic factors for progression-free survival. However, the number of chemotherapy cycles with trastuzumab, palliative radiotherapy, history of breast surgery, and the number of metastatic sites were not significant in this respect.

Conclusion: These results have demonstrated the effectiveness of lapatinib plus capecitabine in metastatic HER2-positive breast cancer patients. Furthermore, unfavorable prognostic factors for progression-free survival were shown to be hormone-negative tumor, de novo metastatic disease, and young age.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信